Table 1 Patient demographics and... | American Society of Hematology

Table 1

Patient demographics and pretreatment characteristics

Dose	300 mg	500 mg	700 mg	1000 mg
No. of patients	10	10	10	10
Median age, y (range)	58 (47-75)	64 (36-66)	56 (34-73)	56 (39-73)
Sex, male/female	5/5	5/5	5/5	5/5
Median body surface area, m² (range)	1.9 (1.8-2.1)	2.0 (1.7-2.1)	2.0 (1.5-2.5)	1.8 (1.5-2.5)
No. of prior treatment regimens, median (range)	2 (1-5)	1.5 (1-4)	2 (1-4)	3 (1-8)
No. of patients with complete response to prior treatment regimens	7	8	2	6
No. of patients previously treated with rituximab	5	2	3	5
Ann Arbor stage
IA	0	0	1	1
IIA	3	1	2	1
IIIA	2	4	2	4
IVA	5	4	2	3
IVB	0	1	3	1
No. of lesions, median (range)	2.5 (0-4)	3 (1-5)	2 (1-3)	2 (1-4)
Sum of the products of the largest perpendicular diameters, mm², indicator lesions (range)	1275 (0*-13 764)	2568 (510-6723)	1767 (817-6135)	2042 (288-8134)

Dose	300 mg	500 mg	700 mg	1000 mg
No. of patients	10	10	10	10
Median age, y (range)	58 (47-75)	64 (36-66)	56 (34-73)	56 (39-73)
Sex, male/female	5/5	5/5	5/5	5/5
Median body surface area, m² (range)	1.9 (1.8-2.1)	2.0 (1.7-2.1)	2.0 (1.5-2.5)	1.8 (1.5-2.5)
No. of prior treatment regimens, median (range)	2 (1-5)	1.5 (1-4)	2 (1-4)	3 (1-8)
No. of patients with complete response to prior treatment regimens	7	8	2	6
No. of patients previously treated with rituximab	5	2	3	5
Ann Arbor stage
IA	0	0	1	1
IIA	3	1	2	1
IIIA	2	4	2	4
IVA	5	4	2	3
IVB	0	1	3	1
No. of lesions, median (range)	2.5 (0-4)	3 (1-5)	2 (1-3)	2 (1-4)
Sum of the products of the largest perpendicular diameters, mm², indicator lesions (range)	1275 (0*-13 764)	2568 (510-6723)	1767 (817-6135)	2042 (288-8134)

Two patients had no indicator lesions.